<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04783649</url>
  </required_header>
  <id_info>
    <org_study_id>CC-001</org_study_id>
    <nct_id>NCT04783649</nct_id>
  </id_info>
  <brief_title>Clinical Validation of Cervical Cancer Screening Methods</brief_title>
  <official_title>Clinical Validation of Cervical Cancer Screening Methods in St. Petersburg, Russia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>N.N. Petrov National Medical Research Center of Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>N.N. Petrov National Medical Research Center of Oncology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single-institution cross-sectional non-inferiority validation study evaluates&#xD;
      alternative techniques and tests for primary cervical cancer screening programs in Russia,&#xD;
      particularly: local cytology staining techniques, local HPV tests.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cervical cytology practices are different across the world. While the Pap test became the&#xD;
      cornerstone of the highly-effective cervical cancer screening in the countries that initially&#xD;
      implemented population-based programs in the 60s and the 70s, alternative staining techniques&#xD;
      were implemented in the Soviet Union. The tradition to apply other staining techniques than&#xD;
      conventional Pap test remained unchanged in the national screening program implemented in the&#xD;
      2010s in Russia. As a new alternative option HPV testing showed effectiveness in screening&#xD;
      women older than 30. The acceptable sensitivity and specificity of a screening test are&#xD;
      crucial in population-based screening, that is why validation against &quot;the gold standard&quot;&#xD;
      should be the first step in the process of program implementation. The objective of this&#xD;
      study is to evaluate alternative techniques and tests for primary cervical cancer screening&#xD;
      programs in Russia, particularly: local cytology staining techniques, local HPV tests in the&#xD;
      population of 25-65 yo women without prior history of malignancy referred to colposcopy&#xD;
      enriched with a population sample of women from several primary healthcare facilities&#xD;
      referred to a primary screening test.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 13, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity</measure>
    <time_frame>24 months</time_frame>
    <description>Cervical screening tests sensitivity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity</measure>
    <time_frame>24 months</time_frame>
    <description>Cervical screening tests specificity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HPV prevalence by type</measure>
    <time_frame>24 months</time_frame>
    <description>HPV prevalence by type based on genotyping in the population sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cervical dysplasia prevalence</measure>
    <time_frame>24 months</time_frame>
    <description>Prevalence of cervical dysplasia in the population sample</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety of cervical smear</measure>
    <time_frame>24 months</time_frame>
    <description>Adverse events after cervical smear</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety of colposcopy and biopsy</measure>
    <time_frame>24 months</time_frame>
    <description>Adverse events after colposcopy and biopsy</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Cervical Dysplasia</condition>
  <condition>Human Papilloma Virus</condition>
  <arm_group>
    <arm_group_label>High risk group</arm_group_label>
    <description>Women in the age group between 25 and 65 years old without prior history of malignancy referred to colposcopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Population sample</arm_group_label>
    <description>A population sample of women in the age group between 25 and 65 years old from several primary healthcare facilities to primary cervical screening</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Papanicolaou cytological test</intervention_name>
    <description>Cervical smear stained using conventional Papanicolaou technique.</description>
    <arm_group_label>High risk group</arm_group_label>
    <arm_group_label>Population sample</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Local cytological test (H&amp;E stain)</intervention_name>
    <description>Cervical smear stained using conventional hematoxylin and eosin staining techniques</description>
    <arm_group_label>High risk group</arm_group_label>
    <arm_group_label>Population sample</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Validated HPV DNA Test</intervention_name>
    <description>Digene HC2 HPV DNA Test</description>
    <arm_group_label>High risk group</arm_group_label>
    <arm_group_label>Population sample</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Local HPV test</intervention_name>
    <description>RealBest DNA HPV HR genotype (differential detection of human papillomavirus types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 DNA)</description>
    <arm_group_label>High risk group</arm_group_label>
    <arm_group_label>Population sample</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Colposcopy</intervention_name>
    <description>Women with positive cytology results are referred to colposcopy and biopsy</description>
    <arm_group_label>High risk group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Cytology and biopsy samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        25-65 year-old women without prior history of malignancy referred to colposcopy enriched&#xD;
        with a population sample of women from several primary healthcare facilities.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Age between 25 and 65 years old Referral to colposcopy or to a primary screening test&#xD;
        Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Prior history of malignancy or cervical dysplasia Prior history of cervical dysplasia&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Gender identity</gender_description>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>N.N. Petrov National Medical Research Center of Oncology</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Smirnova, MD, PhD</last_name>
      <phone>+7 812 439 9555</phone>
      <email>ssmirnova.oa@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 2, 2021</study_first_submitted>
  <study_first_submitted_qc>March 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2021</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Papilloma</mesh_term>
    <mesh_term>Uterine Cervical Dysplasia</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

